Comparison 7. Atovaquone‐proguanil (AP) versus artesunate plus mefloquine (AS plus MQ).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment failure on or by day 14	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2 Treatment failure on or by day 28 adjusted by PCR	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3 Adverse events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 Anorexia	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Dizziness	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.3 Nausea	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.4 Palpitations	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.5 Skin rash	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.6 Sleeping disorders	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.7 Tremor	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.8 Vomiting	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]